尽管试验结果呈阴性，Venetoclax 在 t(11;14) 多发性骨髓瘤中的应用依然成功。

IF 1.8 4区医学 Q3 ONCOLOGY

Oncology-New York Pub Date : 2024-06-10 DOI:10.46883/2024.25921023

Zachary M Avigan, Joshua Richter Md

引用次数: 0

摘要

六月份的热点话题关注 venetoclax 方案在多发性骨髓瘤试验中面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.